Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
A novel approach to pH-Responsive targeted cancer Therapy: Inhibition of FaDu cancer cell proliferation with a pH low insertion Peptide-Conjugated DGAT1 inhibitor.
Int J Pharm. 2024 May 25;657:124132. doi: 10.1016/j.ijpharm.2024.124132. Epub 2024 Apr 17.
Int J Pharm. 2024.
PMID: 38641019
Targeting cancer cells in acidosis with conjugates between the carnitine palmitoyltransferase 1 inhibitor etomoxir and pH (low) insertion peptides.
Deskeuvre M, Lan J, Dierge E, Messens J, Riant O, Corbet C, Feron O, Frédérick R.
Deskeuvre M, et al.
Int J Pharm. 2022 Aug 25;624:122041. doi: 10.1016/j.ijpharm.2022.122041. Epub 2022 Jul 20.
Int J Pharm. 2022.
PMID: 35868479
Item in Clipboard
Investigation of chalcogen bioisosteric replacement in a series of heterocyclic inhibitors of tryptophan 2,3-dioxygenase.
Kozlova A, Thabault L, Dauguet N, Deskeuvre M, Stroobant V, Pilotte L, Liberelle M, Van den Eynde B, Frédérick R.
Kozlova A, et al. Among authors: deskeuvre m.
Eur J Med Chem. 2022 Jan 5;227:113892. doi: 10.1016/j.ejmech.2021.113892. Epub 2021 Oct 7.
Eur J Med Chem. 2022.
PMID: 34678572
Item in Clipboard
Cite
Cite